SEC Comment Letter 0000000000-23-000829 to MetaVia Inc. (MTVA)
MetaVia Inc.
Date: Jan. 25, 2023 · CIK: 0001638287 · Accession: 0000000000-23-000829
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-269365
Letter
United States securities and exchange commission logo January 25, 2023 Joseph Hooker Interim Chief Executive Officer and President NeuroBo Pharmaceuticals, Inc. 200 Berkeley Street, Office 19th Floor Boston, Massachusetts, 02116 Re:NeuroBo Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed January 23, 2023 File No. 333-269365 Dear Joseph Hooker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Phillip D. Torrence
Show Raw Text
United States securities and exchange commission logo
January 25, 2023
Joseph Hooker
Interim Chief Executive Officer and President
NeuroBo Pharmaceuticals, Inc.
200 Berkeley Street, Office 19th Floor
Boston, Massachusetts, 02116
Re:NeuroBo Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed January 23, 2023
File No. 333-269365
Dear Joseph Hooker:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Phillip D. Torrence